lumoxiti
astrazeneca ab - moxetumomab pasudotox - leikēmija, matiņu šūna - antineoplastiski līdzekļi - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
bekemv
amgen technology (ireland) uc - ekulizumabs - hemoglobīnūrija, paroksizmāla - imūnsupresanti - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). pierādījumi par klīniskais ieguvums ir pierādīta pacientiem ar hemolīzi ar klīniskajiem simptomiem(s), kas liecina par augstu slimības aktivitāti, neatkarīgi no asins pārliešanas vēsturi (skatīt 5. iedaļu.
calendula mdf (paziņots 2009.) eļļas ekstrakts
uab ″medicata filia″ - eļļas ekstrakts
glikoze ar c vitamīnu ar aromatizētāju zemene (2016.) tablete
medicata filia, uab - tablete
glikoze ar c vitamīnu ar aromatizētāju apelsīns (2016.) tablete
medicata filia, uab - tablete
glikoze ar c vitamīnu ar aromatizētāju ķirsis (2016.) tablete
medicata filia, uab - tablete
fruktoze ar c vitamīnu (paziņots) tabletes
medicata filia, sas - tabletes
glikoze ar c vitamīnu (paziņots) tabletes
medicata filia , sas - tabletes
ontilyv
bial portela & companhia s.a. - opikapons - parkinsona slimība - anti-parkinsona zāles - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.
ceprotin
takeda manufacturing austria ag - cilvēka olbaltumviela c. - purpura fulminans; protein c deficiency - antitrombotiskie līdzekļi - ceprotin is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.